Evidence map›Paper›PMID 32578945›Full record

ArticleMolecular genetics & genomic medicine2020

Untypically mild phenotype of a patient suffering from Sanfilippo syndrome B with the c.638C>T/c.889C>T (p.Pro213Leu/p.Arg297Ter) mutations in the NAGLU gene.

Karolina Pierzynowska, Arkadiusz Mański, Monika Limanówka, Jolanta Wierzba, Lidia Gaffke, Paulina Anikiej, Grzegorz Węgrzyn

Open access · goldAbstract readCase Reports
In one paragraph

Article in Molecular genetics & genomic medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Heterogeneity of Cognitive Profiles in Children and Adolescents with Mild Intellectual Disability (MID).International journal of environmental research and public health · 2022
    Article
  4. Article
  5. Review
  6. Epidemiology of Mucopolysaccharidoses Update.Diagnostics (Basel, Switzerland) · 2021
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Karolina PierzynowskaDepartment of Molecular Biology, Faculty of Biology, University of Gdańsk, Gdansk, Poland.ORCID 0000-0003-3634-6567
Arkadiusz MańskiPsychological Counselling Centre of Rare Genetic Diseases, University of Gdańsk, Gdansk, Poland.ORCID 0000-0003-3154-9656
Monika LimanówkaDepartement of Pediatrics, Hematology and Oncology, Medical University of Gdańsk, Gdansk, Poland.
Jolanta WierzbaDepartment of Internal and Pediatric Nursing, Medical University of Gdańsk, Gdansk, Poland.ORCID 0000-0003-0290-1243
Lidia GaffkeDepartment of Molecular Biology, Faculty of Biology, University of Gdańsk, Gdansk, Poland.ORCID 0000-0002-0820-7204
Paulina AnikiejPsychological Counselling Centre of Rare Genetic Diseases, University of Gdańsk, Gdansk, Poland.ORCID 0000-0002-7090-211X
Grzegorz WęgrzynDepartment of Molecular Biology, Faculty of Biology, University of Gdańsk, Gdansk, Poland.ORCID 0000-0003-4042-7466
University of Gdańsk · PLGdańsk Medical University · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSanfilippo syndrome B (or mucopolysaccharidosis type IIIB [MPS IIIB]) is a severe inherited metabolic disorder caused by mutations in the NAGLU gene, encoding α-N-acetylglucosaminidase. Dysfunction of this enzyme results in impaired degradation of heparan sulfate, one of glycosaminoglycans, and accumulation of this complex carbohydrate in lysosomes. Severe symptoms occurring in this disease are related to progressive neurodegeneration and include extreme hyperactivity, sleeping problems, aggressive-like behavior, reduced fear, and progressive mental and cognitive deterioration. No cure is currently available for Sanfilippo disease.

methodsClinical characterization of the patient's symptoms has been performed. Biochemical analyses included glycosaminoglycan level determination and measurement of α-N-acetylglucosaminidase activity. Molecular analyses included exome sequencing and detailed analysis of the NAGLU gene. Psychological tests included assessment of attention, communication and behavior.

resultsWe describe a patient with an untypically mild phenotype, who was diagnosed at the age of 13 years. Many cognitive, communication, and motoric functions were preserved in this patient, contrary to vast majority of those suffering from MPS IIIB. The patient is a compound heterozygote (c.638C>T/c.889C>T) in the NAGLU gene, and relatively high residual activity (about 25%) of α-N-acetylglucosaminidase was measured in serum (while no activity of this enzyme could be detected in dry blood spot).

conclusionsWe suggest that the mild phenotype might arise from the partially preserved function of the mutant enzyme (p.Pro213Leu), suggesting the genotype-phenotype correlation in this case.

Indexed as

PhenotypeAcetylglucosaminidaseAdolescentAllelesAttentionCognitionFemaleHumansMovementMucopolysaccharidosis IIIMutation, MissenseAcetylglucosaminidasealpha-N-acetyl-D-glucosaminidasegenotypemucopolysaccharidosisphenotypeSanfilippo syndrome type B

Identifiers

PMID32578945
PMCPMC7507323
OpenAlexW3038097952

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.